Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sentinel lymph node - Why study it: Implications of the B-32 study
Autore:
Harlow, SP; Krag, DN;
Indirizzi:
Univ Vermont, Coll Med, Dept Surg, Burlington, VT 05405 USA Univ Vermont Burlington VT USA 05405 Dept Surg, Burlington, VT 05405 USA
Titolo Testata:
SEMINARS IN SURGICAL ONCOLOGY
fascicolo: 3, volume: 20, anno: 2001,
pagine: 224 - 229
SICI:
8756-0437(200104/05)20:3<224:SLN-WS>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
BREAST-CANCER; AXILLARY DISSECTION; PREMENOPAUSAL WOMEN; CLINICAL RESEARCH; GAMMA-PROBE; BIOPSY; CARCINOMA; RADIOTHERAPY; CHEMOTHERAPY; MULTICENTER;
Keywords:
breast cancer; sentinel nodes; clinical trials;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Krag, DN Univ Vermont, Coll Med, Dept Surg, Given Bldg E309, Burlington, VT 05405 USA Univ Vermont Given Bldg E309 Burlington VT USA 05405 VT 05405 USA
Citazione:
S.P. Harlow e D.N. Krag, "Sentinel lymph node - Why study it: Implications of the B-32 study", SEM SURG ON, 20(3), 2001, pp. 224-229

Abstract

Surgical removal of the regional lymph nodes by a level I and level II axillary dissection remains the standard of care for patients with surgically resectable breast cancer. Axillary dissection provides accurate pathologic staging and excellent regional disease control, and likely provides a smallbenefit in patient survival. Axillary dissection, however, is associated with significant patient morbidity. Sentinel lymph node (SLN) biopsy procedures have been found to provide very accurate pathologic staging when compared to axillary dissection; however, their effect on regional disease control and patient survival is not yet known. The National Cancer Institute (NCI) has sponsored a Phase III prospective, randomized clinical trial (the B-32 trial) through the National Adjuvant Breast and Bowel Project (NSABP), tocompare results of patients treated with SLN biopsy alone vs. SLN biopsy with completion axillary node dissection in patients with clinically node-negative breast cancer. Results of this trial will provide evidence of the safety of SLN biopsy procedures in the management of patients with breast cancer. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 08:29:41